ArticleESMO open2025
Pathological complete response and survival after neoadjuvant chemotherapy in patients with stage I TNBC: a registry-based study.
Article in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Contemporary therapy for small node-negative triple-negative breast cancer: a retrospective cohort study.Breast cancer research and treatment · 2026Observational
- Surgery-first versus neoadjuvant chemotherapy in stage I (cT1c) triple-negative breast cancer: A critical reappraisal.Breast (Edinburgh, Scotland) · 2026Review
- Role of Endogenous Myoglobin in Anthracycline Response in Breast Cancer.Biomolecules · 2026Article
- Development and internal validation of a nomogram based on HER2 status for predicting pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer.Translational cancer research · 2026Article
- Novel pyridine-based chalcone analogs and triple negative breast cancer: potential therapy & molecular pathways.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPathological complete response (pCR) after neoadjuvant chemotherapy (NACT) is a strong prognostic factor in patients with early-stage triple-negative breast cancer (TNBC). One-third of all patients with early-stage TNBC have stage I disease. Chemotherapy is recommended for most patients with stage I TNBC with an increasing use in the neoadjuvant setting supported by recent guidelines. However, little is known on the chemotherapy benefit for stage I TNBC, in particular the likelihood of a pCR and the prognostic value of pCR in this setting. PATIENTS AND
methodsPatients with cT1N0M0 TNBC who received standard of care NACT followed by surgery between 2012 and 2022 were identified from the Netherlands Cancer Registry. Baseline factors associated with pCR (ypT0/is, ypN0) and the impact of pCR on overall survival (OS) were evaluated.
resultsA total of 1144 patients treated with anthracycline-taxane-based NACT were identified. Most patients had cT1N0 disease [n = 1077 (94%)] of no special subtype [n = 1034 (90%)]. In total, 656 patients (57.3%) had a pCR. Younger age [odds ratio (OR) 1.78, 95% confidence interval (CI) 1.38-2.30], higher tumor grade [OR 2.11, 95% CI 1.58-2.81] and smaller tumors [OR 2.03, 95% CI 1.15-3.69] were significantly associated with a higher likelihood of pCR, while patients with a lobular carcinoma were less likely to have a pCR (OR 0.17, 95% CI 0.03-0.67). Platinum-based treatment did not significantly improve the pCR rate (P = 0.9). pCR was associated with a better OS [adjusted hazard ratio (aHR) 0.23, 95% CI 0.11-0.45], with a 5-year OS of 97% versus 90% for patients with and without a pCR, respectively. Of 488 patients with residual disease, 280 (57.4%) received adjuvant capecitabine, which was not significantly associated with improved OS [aHR 0.65, 95% CI 0.30-1.44].
conclusionsData from this real-world nationwide Dutch registry on neoadjuvant chemotherapy for stage I TNBC, with the majority of patients having cT1cN0 disease of no special subtype, suggests pCR to be associated with a favorable long-term outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.